Literature DB >> 29187440

Liprin-α4 as a Possible New Therapeutic Target for Pancreatic Cancer.

Akio Yamasaki1, Kazunori Nakayama1, Akira Imaizumi2, Makoto Kawamoto1, Akiko Fujimura1, Yasuhiro Oyama1, Shuntaro Nagai3, Kosuke Yanai1, Hideya Onishi4.   

Abstract

BACKGROUND/AIM: In pancreatic cancer, where the microenvironment is extremely hypoxic, analyzing signal transduction under hypoxia is thought to be significantly important. By investigating microarray analysis of pancreatic cancer cells cultured under both normoxia and hypoxia, we found that the expression of leukocyte common antigen-related (LAR)-interacting protein (liprin)-α4 was extremely increased under hypoxia compared to under normoxia.
MATERIALS AND METHODS: In the present study, the biological significance of liprin-α4 in pancreatic cancer was investigated and whether liprin-α4 has potential as a therapeutic target for pancreatic cancer was estimated.
RESULTS: Suppression of liprin-α4 reduced proliferation of pancreatic cancer cells both in vitro and in vivo. Inhibition of liprin-α4 also reduced invasiveness through the suppression of endothelial-mesenchymal transition. Stimulation by liprin-α4 was through phosphoinositide 3-kinase and mitogen-activated protein kinase signaling pathways.
CONCLUSION: Liprin-α4 plays a pivotal role in inducing malignant phenotypes such as increased proliferation and invasion in pancreatic cancer, and that liprin-α4 could be a new effective therapeutic target for pancreatic cancer. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Liprin-α4; pancreatic cancer cells

Mesh:

Substances:

Year:  2017        PMID: 29187440     DOI: 10.21873/anticanres.12122

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Systematic Identification of Genomic Markers for Guiding Iron Oxide Nanoparticles in Cervical Cancer Based on Translational Bioinformatics.

Authors:  Haohan Zhou; Jiayi Tian; Hongyu Sun; Jiaying Fu; Nan Lin; Danni Yuan; Li Zhou; Meihui Xia; Liankun Sun
Journal:  Int J Nanomedicine       Date:  2022-06-29

2.  FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patients.

Authors:  Kiyoshi Saeki; Hideya Onishi; Satoko Koga; Shu Ichimiya; Kazunori Nakayama; Yasuhiro Oyama; Makoto Kawamoto; Kukiko Sakihama; Takeo Yamamoto; Ryota Matsuda; Yoshihiro Miyasaka; Masafumi Nakamura; Yoshinao Oda
Journal:  J Cancer       Date:  2020-02-10       Impact factor: 4.207

3.  The role of S100A4 for bone metastasis in prostate cancer cells.

Authors:  Bongjun Kim; Suhan Jung; Haemin Kim; Jun-Oh Kwon; Min-Kyoung Song; Min Kyung Kim; Hyung Joon Kim; Hong-Hee Kim
Journal:  BMC Cancer       Date:  2021-02-06       Impact factor: 4.430

4.  A Glycolysis-Related Five-Gene Signature Predicts Biochemical Recurrence-Free Survival in Patients With Prostate Adenocarcinoma.

Authors:  Zijun Xu; Lijuan Xu; Liping Liu; Hai Li; Jiewen Jin; Miaoguan Peng; Yanrui Huang; Haipeng Xiao; Yanbing Li; Hongyu Guan
Journal:  Front Oncol       Date:  2021-04-19       Impact factor: 6.244

5.  PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2.

Authors:  Ru Zhao; Tingting Feng; Lin Gao; Feifei Sun; Qianqian Zhou; Xin Wang; Junmei Liu; Wenbo Zhang; Meng Wang; Xueting Xiong; Wenqiao Jia; Weiwen Chen; Lin Wang; Bo Han
Journal:  J Exp Clin Cancer Res       Date:  2022-04-05

6.  Modeling preeclampsia using human induced pluripotent stem cells.

Authors:  Mariko Horii; Robert Morey; Tony Bui; Ojeni Touma; Katharine K Nelson; Hee-Young Cho; Hannah Rishik; Louise C Laurent; Mana M Parast
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.